Share this page
Print this page
Email alert
ISOFORM-SELECTIVE PI3K INHIBITORS
In addition to CAL-101, CAL-263, and CAL-120, Calistoga Pharmaceuticals has a portfolio of isoformselective PI3K product candidates in preclinical evaluation. Using our library of pharmacologic tools, the research team is elucidating new understanding of this pathway, the functions of specific isoforms of PI3 kinase, and the opportunity to utilize isoform-selective PI3K inhibitors to impact multiple disease settings. Calistoga Pharmaceuticals is also continuing to develop follow on compounds for cancer and inflammatory diseases.
Research
Isoform-Selective PI3K Inhibitors
Follow-on Compounds and
Other Therapeutic Opportunities